In GBM, CD155 found to be consistently expressed across a wide range of models, including laboratory and primary GBM cell lines, patient-derived explant cells, GBM biopsy-derived xenografts, and surgically resected tumor tissues [161,162], underscoring its relevance as a potential therapeutic target in this aggressive brain tumor. The gene discussed is PVR; the disease is neoplasm.